






PHARMACEUTICAL 2024

Werewolf Therapeutics Inc Rank 99 of 309

The relative strengths and weaknesses of Werewolf Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Werewolf Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 68% points. The greatest weakness of Werewolf Therapeutics Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 284%, being 70% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	138,370
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	19,378
Liabilities, Non-Current	11,425
Other Assets	28,505
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	32,656
Other Net Income	23,078
Other Revenues	0
Property and Equipment	7,958
Research and Development	41,776
Selling, General and Administrative Expense	18,670

Output Variable	Value in 1000 USD
Assets	174,833
Liabilities	63,459
Expenses	60,446
Revenues	0
Stockholders Equity	111,374
Net Income	-37,368
Comprehensive Net Income	-37,368
BaseVar	160,908
ECR before LimitedLiability	172%
Economic Capital Ratio	284%